ReviewMuscle & nerve2009
Applying proteomics to the diagnosis and treatment of ALS and related diseases.
Review in Muscle & nerve, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 29 citations in OpenAlex.
- Machine Learning Reveals Protein Signatures in CSF and Plasma Fluids of Clinical Value for ALS.Scientific reports · 2018Article
- Specific Metabolome Profile of Exhaled Breath Condensate in Patients with Shock and Respiratory Failure: A Pilot Study.Metabolites · 2016Article
- Clinical Trial Designs in Amyotrophic Lateral Sclerosis: Does One Design Fit All?Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2015Review
- Blood volatile organic compounds as potential biomarkers for amyotrophic lateral sclerosis: an animal study in the SOD1 G93A mouse.Journal of molecular neuroscience : MN · 2015Article
- Matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) in amyotrophic lateral sclerosis (ALS).Journal of neural transmission (Vienna, Austria : 1996) · 2014Review
- Amyotrophic lateral sclerosis: a focus on disease progression.BioMed research international · 2014Review
- SMA-MAP: a plasma protein panel for spinal muscular atrophy.PloS one · 2013Article
- On the development of markers for pathological TDP-43 in amyotrophic lateral sclerosis with and without dementia.Progress in neurobiology · 2011Review
- Biomarkers in amyotrophic lateral sclerosis: opportunities and limitations.Nature reviews. Neurology · 2011Review
- New considerations in the design of clinical trials for amyotrophic lateral sclerosis.Clinical investigation · 2011Article
- Combination of neurofilament heavy chain and complement C3 as CSF biomarkers for ALS.Journal of neurochemistry · 2011Article
- Discovery and verification of amyotrophic lateral sclerosis biomarkers by proteomics.Muscle & nerve · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Protein-based biomarkers for amyotrophic lateral sclerosis (ALS) and other motor neuron diseases (MNDs) have many potential clinical utilities, including diagnostic, prognostic, and drug development indications. During the past decade a number of potential protein biomarkers have been proposed for MNDs. Further verification studies, followed by large validation and qualification studies, are required to advance these initial discoveries toward clinical use. Study of additional patient populations, including disease mimics, is required during the validation phase of biomarker development. Important regulatory issues are discussed that will affect the timing and strategy for biomarker assay development in ALS and other MNDs. The continued development of protein biomarkers for MNDs requires extensive collaboration between academic clinicians and scientists in conjunction with the biotechnology and pharmaceutical industries.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.